RE:RE:Echelon Target $3.40.It looks like most 12 month target prices for the company range from $2.00 to $2.90 now. That's down a bit as analysts adjusted their models for higher discount rates now being reflected more generally in the markets. Very few analysts adjusted their fundamental targets for the company.
As an aside, with the stock now trading where it is we're seeing some implications of the poor capital management decisions by THNK leadership come to light, specifically the issuance of shares at a future date and stock price. Small cap share prices can get absolutely decimated in bear markets even if that share price is disconnected with a company's fundamentals. Management has made several moves where they intended to pay for acquisitions and services via share issuance, which is why Oak Hill has now recieved a whopping nearly 75K shares to cover their $60,000 bill. If the share price continues its decent it starts creating possibilities that other obligations (e.g. BioPhara $3.25mm owed via shares) are met by floating a large share issuance at low prices therby diluting existing shareholders significantly. The lower the share price goes the greater the prospective dilution and as a result the shares sell off even more. It can become a vicious cycle. Hopefully management can difuse these situations by re-negotiating a cash offer instead (the recipients should be in favour of this), which frankly may be a use of funds for the recent $10mm drawn on the Beedie Capital convertible (since those are convertible at a much more reasonable $1.44 share price).